



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

23 Aug 2021 (#27)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

[NOT-HL-21-024](#) Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue). This Notice of Special Interest is a reissue of [NOT-HL-20-796](#). The purpose of this NOSI is to advise potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest to support early phases of innovative bioengineering projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with the NHLBI Catalyze Program, and it does focus on new investigator-initiated ideas that will feed into the Catalyze pipeline. Submit applications for this initiative using the following funding opportunity announcement (FOA):

[PA-20-195](#)- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed).

[NOT-MH-21-330](#) Notice of Special Interest (NOSI): Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations. NIH Institutes, Centers, and Offices participating in the Social, Behavioral, and Economic Impacts of COVID-19 in Vulnerable and Health Disparity Populations initiative are issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the understanding and response to the Coronavirus Disease 2019 (COVID-19) pandemic and help us prepare more effectively for future public health emergencies. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, there are additional urgent public health needs, particularly in populations who experience health disparities and in vulnerable populations. The purpose of this Notice is to 1) emphasize the roles and impacts of interventions, particularly those under the umbrella of digital health, as well as community-engaged and multi-level interventions in healthcare settings to address access, reach, delivery, engagement, effectiveness, scalability, and sustainability of services that are utilized during and following the pandemic, and 2) encourage the leveraging of existing large-scale data sources with broad population coverage to improve prediction of various mitigation efforts (including vaccinations, masking, and physical distancing to inform the public health response) on transmission

reduction and on social and economic impacts, and assess the downstream health and healthcare access effects, with an emphasis on underserved and vulnerable populations. Additionally, the use of large-scale data sources to study the indirect health impacts of the pandemic and subsequent social and economic changes is needed to understand the costs and benefits of various COVID-19 mitigation strategies. This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through September 8, 2024. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs)

[PA-20-183](#) - Research Project Grant (Parent R01 Clinical Trial Required)

[PA-20-184](#) - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

[PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

[PAR-21-130](#) - Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)

[PAR-20-154](#) - Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

[PAR-21-160](#) - NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

Funding Opportunity Announcements (FOA)

1. Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)

Letter of Intent: 60 days prior to the application due date

Hyperlink: [PAR-21-315](#)

Type: UG3/UH3

Application Due Date: October 20, 2021, February 18, 2022, June 20, 2022, October 18, 2022; February 21, 2023 Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website: <https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech>

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project. Application budgets should only cover the work that will be performed by the PD/PI and his/her staff. The NIH will pay Blueprint MedTech contractors and consultants directly for their work; therefore, these expenses should not be included in the budget for this application. The proposed project period for the UG3 phase must not exceed 4 years. The proposed project period for the UH3 phase must not exceed 4 years. The total duration of the UG3 and UH3 may not exceed 5 years..

2. Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-026](#)

Type: R01

Application Due Date: November 08, 2021 Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit studies that will advance the mechanistic understanding of small vessel vascular contributions to cognitive impairment and dementia (VCID) through the development of new technologies and innovative methods that enable the imaging and/or functional assessment of the small blood and lymphatic vessels and perivascular spaces of the brain. This program aims to facilitate the development of tools and technology to image, profile and/or mechanistically characterize CNS small blood and lymphatic vessels in Alzheimer's Disease and Alzheimer's Disease-Related Dementia (AD/ADRD) animal models or patient populations. The overall goal is to use such technologies or methods to elucidate the mechanisms that link CNS small blood and lymphatic vessel dysfunction to dementia outcomes in the AD/ADRDs, their potential role in repair processes, and their response to therapies. Preclinical studies of small vessel VCID in vitro and/or animal models and pilot human subject studies (that do not meet the NIH definition of clinical trial) are appropriate for this FOA.

Budget: NINDS intends to commit \$6,500,000 total costs per year in FY 2022-2027 to fund five awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to \$499,000 direct costs/year and need to reflect the actual needs of the proposed project.

3. Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-316](#)

Type: R01

Application Due Date: October 05, 2021, February 05, 2022, June 05, 2022, October 05, 2022; February 05, 2023; June 05, 2023 Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities that strengthen the public health impact of NIMH-supported research as described in [Goal 4 of the NIMH Strategic Plan](#).

Proposed research should seek to:

1. Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development;
2. Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues;
3. Integrate and analyze large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches;
4. Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed budget. However, applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request \$500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Deciphering Immune-CNS interactions in people living with HIV on Anti-Retroviral therapy (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-21-250](#)

Type: R01

Application Due Date: December 07, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support studies to better comprehend the mechanisms contributing to the CNS co-morbidities in people living with HIV on Anti-Retroviral therapy by deciphering the Immune-Central Nervous System (CNS) interactions. Applications testing a fully conceptualized and hypothesis-based premise founded on adequate preliminary data are appropriate for this FOA. Applicants pursuing exploratory and high-risk research projects should be submitted to the companion R21 announcement, RFA-MH-21-251. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Budget: NIMH intends to commit a total of \$2,000,000 in FY 2022 to fund 3-5 awards in response to this FOA and the companion FOA. Future year amounts will depend on annual appropriations. NINDS intends to commit a total of \$1,500,000 in FY 2022 to fund 3-5 awards in response to this FOA and the companion FOA. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. Deciphering Immune-CNS interactions in HIV utilizing in-vitro and in-vivo model systems (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-21-251](#)

Type: R21

Application Due Date: December 07, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support studies to comprehend the mechanisms contributing to the CNS co-morbidities in people living with HIV (PLHIV) on Anti-Retroviral therapy (ART) by deciphering the Immune-Central Nervous System (CNS) interactions utilizing novel in-vitro and in-vivo model systems. Exploratory and high-risk research projects are appropriate for this FOA. Applications proposing to test a fully conceptualized and hypothesis-based premise founded on adequate preliminary data should be submitted to the companion R01 announcement, RFA-MH-21-250. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Budget: NIMH intends to commit a total of \$2,000,000 in FY 2022 to fund 3-5 awards in response to this FOA and the companion FOA. Future year amounts will depend on annual appropriations. NINDS intends to commit a total of \$1,500,000 in FY 2022 to fund 3-5 awards in response to this FOA and the companion FOA. Future year amounts will depend on annual appropriations. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105